title: Changes in Cancer Treatment: Mabs, Mibs, Mids, Nabs, and Nibs.
abstract: Cancer therapeutics has been growing in an unprecedented fashion and has evolved rapidly in the past two decades. Specific gene mutation, protein dysfunction and dysregulation, intracellular signaling pathways, and immune modulation have been targeted. These therapeutic advances came largely because of improved understanding of the pathobiology of cancer at the genetic and molecular levels. This article addresses the need of novice nurses for cancer treatment-related information and evidence-based nursing care of patients diagnosed with cancer while undergoing novel and breakthrough therapeutics.
authors.affiliation: School of Nursing, DePaul University, 990 West Fullerton Avenue, Suite 3000, Chicago, IL 60614, USA. Electronic address: jtariman@depaul.edu.
authors.forename: Joseph D
authors.initials: JD
authors.lastname: Tariman
mesh_terms: D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D055318:Evidence-Based Nursing / Q000379:methods*; D006801:Humans; D007167:Immunotherapy; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000235:genetics* / Q000628:therapy*; D061988:Proteasome Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000378:metabolism
chemical_list: D004791:Enzyme Inhibitors; D061988:Proteasome Inhibitors; D011505:Protein-Tyrosine Kinases
keywords: Cancer therapeutics; Immunomodulatory drug; Monoclonal antibody; Nanoparticle albumin-bound drug; Nursing care; Proteasome inhibitor; Targeted therapy; Tyrosine kinase inhibitor